Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)

被引：1

作者：

Berenson, J. R.

Yellin, O.

Boccia, R. V.

Flam, M. S.

Wong, S.

Batuman, O.

Moezi, M. M.

Woytowitz, D. V., Jr.

Duvivier, H. L.

Nassir, Y.

Swift, R.

机构：

[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA USA

[2] Oncotherapeutics, W Hollywood, CA USA

[3] Ctr Canc & Blood Disorders, Bethesda, MD USA

[4] Hematol Oncol Med Grp Fresno, Fresno, CA USA

[5] Western Univ Hlth Sci, Pomona, CA USA

[6] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

[7] Florida Oncol Associates, Orange Pk, FL USA

[8] Florida Canc Specialists, Port Charlotte, FL USA

[9] James R Berenson MD Inc, W Hollywood, CA USA

[10] Canc Care Inst, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.8550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

8550

引用

页数：1